14 completed, 1 active not recruiting, 1 withdrawn. 16 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 14, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Withdrawn 1 |
Follow LY-2157299: new trials by email Literature Review of LY-2157299 trials Research Report on LY-2157299
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Galunisertib Combined With Capecitabine in Advanced CRC With PM Galunisertib plus capecitabine - Colorectal Cancer Metastatic, Peritoneal Carcinomatosis | Phase 1 / Phase 2 | Active not recruiting | The Netherlands Cancer Institute | 31 | 2023-07-28 | 2026-07-13 |
| Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer Galunisertib - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Withdrawn | The Netherlands Cancer Institute | 2018-08-24 | 2019-07-24 | |
| Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Galunisertib, Paclitaxel, Carboplatin - Carcinosarcoma, Ovarian | Phase 1 | Completed | University of Oklahoma | 26 | 2017-08-23 | 2024-08-07 |
| Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC) Galunisertib 150mg by mouth twice a day, Stereotactic Body Radiotherapy (SBRT) - ADVANCED HEPATOCELLULAR CARCINOMA (HCC) | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 15 | 2017-03-30 | 2022-03-25 |
| A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer Galunisertib, Durvalumab - Metastatic Pancreatic Cancer | Phase 1 | Completed | Eli Lilly and Company | 37 | 2016-06-15 | 2019-08-05 |
| Study of Galunisertib in Healthy Participants Galunisertib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 40 | 2016-04-01 | 2016-07-04 |
| Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer Galunisertib, Laboratory Biomarker Analysis, Paclitaxel - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | Vanderbilt-Ingram Cancer Center | 29 | 2016-03-01 | 2023-11-22 |
| A Study of Galunisertib on the Immune System in Participants With Cancer Galunisertib - Neoplasm | Phase 1 | Completed | Eli Lilly and Company | 10 | 2015-05-01 | 2016-10-05 |
| A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Galunisertib, Nivolumab - Solid Tumor, Non-Small Cell Lung Cancer Recurrent | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 41 | 2015-01-01 | 2021-09-09 |
| A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) LY2157299, Sorafenib - Hepatocellular Carcinoma | Phase 1 | Completed | Eli Lilly and Company | 9 | 2014-11-12 | 2020-02-05 |
| A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body LY2157299, Gemcitabine - Pancreatic Neoplasms | Phase 1 | Completed | Eli Lilly and Company | 6 | 2014-05-01 | 2016-02-10 |
| A Study of LY2157299 in Healthy Participants LY2157299 - Healthy Volunteers | Phase 1 | Completed | Eli Lilly and Company | 16 | 2013-10-01 | 2013-12-04 |
| Study of LY2157299 in Japanese Participants With Cancer LY2157299 - Neoplasms, Neoplasm Metastasis | Phase 1 | Completed | Eli Lilly and Company | 12 | 2012-11-01 | 2014-07-01 |
| A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer Galunisertib, Gemcitabine, Placebo - Neoplasms, Neoplasm Metastasis | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 170 | 2011-06-01 | 2018-05-16 |
| A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma LY2157299, Radiation, Temozolomide - Glioma | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 75 | 2011-04-01 | 2017-02-16 |
| A Dose-Escalation Study in Participants With Recurrent Malignant Glioma LY2157299, Lomustine - Glioma | Phase 1 | Completed | Eli Lilly and Company | 66 | 2005-12-15 | 2024-11-07 |
Neoplasms (3) · Pancreatic Neoplasms (3) · Glioma (2) · Neoplasm Metastasis (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinosarcoma (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Peritoneal Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Eli Lilly and Company (11) · The Netherlands Cancer Institute (2) · Abramson Cancer Center at Penn Medicine (1) · University of Oklahoma (1) · Vanderbilt-Ingram Cancer Center (1)
United States (10) · Spain (5) · Japan (3) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Belgium (1) · South Korea (1) · United Kingdom (1)
A Bardelli, Prof (1) · A Cervantes, Prof (1) · F Ciardiello, Prof (1) · J Tabernero, Prof (1) · Kathleen Moore, MD (1) · Kim Reiss Binder, MD (1) · R Bernards, Prof (1) · R Salazar, MD, PhD (1) · S Siena, Prof (1) · S Tejpar, Prof (1) · Vandana Abramson, MD (1)
PMID 26526984, PMID 30887178, PMID 31903699, PMID 32140889, PMID 33688022, PMID 37507657
2015 (3), 2016 (1), P30CA068485 (1)